https://ogg1signaling.com/inde....x.php/actual-qualiti
Patients with lenalidomide-refractory multiple myeloma, in this phase 3, randomized, open-label trial, were allocated to receive cilta-cel or an alternative effective standard therapy chosen by their physician. Each patient's prior treatment encompassed one to three distinct treatment phases. The study's main evaluation criteria were the time period in which patients remained progression-free. Randomized treatment groups included 208 patients receiving cilta-cel and
پسند
تبصرہ
بانٹیں
